

=> d his

(FILE 'HOME' ENTERED AT 16:38:29 ON 22 JAN 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 16:38:44 ON 22 JAN 2003

L1 8417 S AAV OR ADENO-ASSOCIATED (W) VIRUS
L2 39510 S (CNS OR CENTRAL (W) NERVOUS (W) SYSTEM) (6A) (DISEASE OR DISORDER)
L3 364965 S (PARKINSON OR ALZHEIMER) (3A) DISEASE OR GLIOMA OR GLIOBLASTOMA
L4 53458 S BRAIN (3A) (TUMOR OR CANCER)
L5 436225 S L2 OR L3 OR L4
L6 89 S L1(8A)L5
L7 117 S CONVECTION (3A) ENHANCED (3A) DELIVERY
L8 3 S L6 AND L7
L9 3 DUP REM L8 (0 DUPLICATES REMOVED)

=> d bib ab 1-3 19

L9 ANSWER 1 OF 3 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 2002:236247 SCISEARCH
GA The Genuine Article (R) Number: 529FG
TI Gene therapeutic approaches to the treatment of Parkinson's disease
AU Bowers W J; Maguire-Zeiss K A; Harvey B K; Federoff H J (Reprint)
CS Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Div Mol Med & Gene
Therapy, 601 Elmwood Ave, Rochester, NY 14642 USA (Reprint); Univ
Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Div Mol Med & Gene
Therapy, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept
Neurol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept
Neurobiol & Anat, Rochester, NY 14642 USA
CYA USA
SO CLINICAL NEUROSCIENCE RESEARCH, (DEC 2001) Vol. 1, No. 6, pp. 483-495.
Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
OXFORD OX5 1GB, OXON, ENGLAND.
ISSN: 1566-2772.
DT General Review; Journal
LA English
REC Reference Count: 177
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Parkinson's disease (PD) is a neurodegenerative illness of unknown
etiology that presently has no cure. Symptoms of this progressively
debilitating disease include bradykinesia, resting tremor, rigidity, gait
abnormalities, and postural instability that can be transiently alleviated
via continued administration of the drug, L-DOPA. However, following
prolonged usage, the effectiveness of this clinical treatment
substantially diminishes. To that end, novel therapies for amelioration of
symptoms and/or permanent cure of PD need to be developed. The utility of
gene transfer modalities for PD treatment holds tremendous promise, but
gene therapy is yet unproven within the realm of the **central**
nervous system. This discourse proposes possible
disease targets and reviews the present standing of adenovirus-,
adeno-associated virus-, herpes virus-, and
non-virus-based gene transfer technologies in regard to how they have been
applied in *in vitro* and *in vivo* models of PD. Identification of disease
mechanisms, potential points of therapeutic intervention, and an
understanding of presently utilized gene delivery vehicles will facilitate
the development of potentially safe and efficacious modalities for therapy
of PD. (C) 2001 Elsevier Science B.V. All rights reserved.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 2000:442913 CAPLUS
DN 134:36883
TI **Convection-enhanced delivery of AAV vector**
in parkinsonian monkeys; *in vivo* detection of gene expression and
restoration of dopaminergic function using pro-drug approach

AU Bankiewicz, Krys S.; Eberling, Jamie L.; Kohutnicka, Malgorzata; Jagust, William; Pivirotto, Phillip; Bringas, John; Cunningham, Janet; Budinger, Thomas F.; Harvey-White, Judith
 CS Molecular Therapeutics Section, LMMN, NINDS, Bethesda, MD, 20892, USA
 SO Experimental Neurology (2000), 164(1), 2-14
 CODEN: EXNEAC; ISSN: 0014-4886
 PB Academic Press
 DT Journal
 LA English
 AB Using an approach that combines gene therapy with arom. l-amino acid decarboxylase (AADC) gene and a pro-drug (l-dopa), dopamine, the neurotransmitter involved in Parkinson's disease, can be synthesized and regulated. Striatal neurons infected with the AADC gene by an adeno-assocd. viral vector can convert peripheral l-dopa to dopamine and may therefore provide a buffer for unmetabolized l-dopa. This approach to treating Parkinson's disease may reduce the need for l-dopa/carbidopa, thus providing a better clin. response with fewer side effects. In addn., the imbalance in dopamine prodn. between the nigrostriatal and mesolimbic dopaminergic systems can be cor. by using AADC gene delivery to the striatum. We have also demonstrated that a fundamental obstacle in the gene therapy approach to the central nervous system, i.e., the ability to deliver viral vectors in sufficient quantities to the whole brain, can be overcome by using **convection-enhanced delivery**. Finally, this study demonstrates that positron emission tomog. and the AADC tracer, 6-[18F]fluoro-l-m-tyrosine, can be used to monitor gene therapy in vivo. Our therapeutic approach has the potential to restore dopamine prodn., even late in the disease process, at levels that can be maintained during continued nigrostriatal degeneration. (c) 2000 Academic Press.

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:763910 CAPLUS
 DN 132:19624
 TI **Convection-enhanced delivery of AAV vectors to the CNS and therapeutic use thereof**
 IN Bankiewicz, Krys; Cunningham, Janet; Eberling, Jamie L.
 PA Avigen, Inc., USA; Lawrence Berkeley National Laboratory
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9961066	A2	19991202	WO 1999-US11687	19990526
	WO 9961066	A3	20000504		
	W: CA, JP RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2329259	AA	19991202	CA 1999-2329259	19990526
	EP 1080202	A2	20010307	EP 1999-925906	19990526
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6309634	B1	20011030	US 1999-320171	19990526
	JP 2002516295	T2	20020604	JP 2000-550525	19990526
	US 2002141980	A1	20021003	US 2001-887854	20010621
PRAI	US 1998-86949P	P	19980527		
	US 1999-134748P	P	19990518		
	US 1999-320171	A1	19990526		
	WO 1999-US11687	W	19990526		
AB	Methods of delivering viral vectors, particularly recombinant adeno-assocd. virions, to the CNS are provided. Also provided are methods				

of treating Parkinson's Disease.

=>

=> d his

(FILE 'HOME' ENTERED AT 15:59:28 ON 22 JAN 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:59:40 ON 22 JAN 2003

L1 8417 S AAV OR ADENO-ASSOCIATED (W) VIRUS
L2 39510 S (CNS OR CENTRAL(W) NERVOUS (W) SYSTEM) (6A) (DISEASE OR DISORDER)
L3 380042 S (PARKINSON OR ALZHEIMER) (3A) DISEASE OR GLIOMA OR NEUROBLASTOM
L4 416034 S L2 OR L3
L5 250 S L1(S)L4
L6 83 S L1(8A)L4
L7 54 DUP REM L6 (29. DUPLICATES REMOVED)

=> d 20-54 au ti so 17

L7 ANSWER 20 OF 54 SCISEARCH COPYRIGHT 2003 ISI (R)
AU Bowers W J; Maguire-Zeiss K A; Harvey B K; Federoff H J (Reprint)
TI Gene therapeutic approaches to the treatment of Parkinson's disease
SO CLINICAL NEUROSCIENCE RESEARCH, (DEC 2001) Vol. 1, No. 6, pp. 483-495.
Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
OXFORD OX5 1GB, OXON, ENGLAND.
ISSN: 1566-2772.

L7 ANSWER 21 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Sanchez-Pernaute, Rosario; Harvey-White, Judith; Cunningham, Janet;
Bankiewicz, Krys S.
TI Functional effect of adeno-associated virus mediated gene transfer of
aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned
rats
SO Molecular Therapy (2001), 4(4), 324-330
CODEN: MTOHCK; ISSN: 1525-0016

L7 ANSWER 22 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mochizuki, Hideki; Mizuno, Yoshikuni
TI Mitochondria and degenerative disorder
SO Igaku no Ayumi (2001), 199(4), 263-267
CODEN: IGAYAY; ISSN: 0039-2359

L7 ANSWER 23 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU Du Xucang (1); Ren Huimin (1); Hu Haitao (1)
TI Gene therapy vector based on adeno-associated virus type-2.
SO Xi'an Yike Daxue Xuebao, (Apr., 2001) Vol. 22, No. 2, pp. 100-102. print.
ISSN: 0258-0659.

L7 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Klein, Ronald L.; Mandel, Ronald J.; Muzyczka, Nicholas
TI Adeno-associated virus vector-mediated gene transfer to somatic cells in
the central nervous system
SO Advances in Virus Research (2000), 55, 507-528
CODEN: AVREA8; ISSN: 0065-3527

L7 ANSWER 25 OF 54 MEDLINE DUPLICATE 6
AU Ozawa K; Fan D S; Shen Y; Muramatsu S; Fujimoto K; Ikeguchi K; Ogawa M;
Urabe M; Kume A; Nakano I
TI Gene therapy of Parkinson's disease using
adeno-associated virus (AAV)
vectors.
SO JOURNAL OF NEURAL TRANSMISSION. SUPPLEMENTUM, (2000) (58) 181-91. Ref: 56
Journal code: 0425126. ISSN: 0303-6995.

L7 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Ozawa, K.; Fan, D. -S.; Shen, Y.; Muramatsu, S.; Fujimoto, K.; Ikeguchi,

TI K.; Ogawa, M.; Urabe, M.; Kume, A.; Nakano, I.
Gene therapy of Parkinson's disease using
adeno-associated virus (AAV) vectors

SO Advances in Research on Neurodegeneration (2000), 7(7th International
Winter Conference on Neurodegeneration, 1999), 181-191
CODEN: ARNEFX; ISSN: 1068-719X

L7 ANSWER 27 OF 54 MEDLINE DUPLICATE 7
AU Bjorklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel R J
TI Towards a neuroprotective gene therapy for Parkinson's
disease: use of adenovirus, AAV and lentivirus vectors
for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson
model.

SO BRAIN RESEARCH, (2000 Dec 15) 886 (1-2) 82-98. Ref: 71
Journal code: 0045503. ISSN: 0006-8993.

L7 ANSWER 28 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Bankiewicz, Krys S.; Eberling, Jamie L.; Kohutnicka, Malgorzata; Jagust, William; Piviroto, Phillip; Bringas, John; Cunningham, Janet; Budinger, Thomas F.; Harvey-White, Judith
TI Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach

SO Experimental Neurology (2000), 164(1), 2-14
CODEN: EXNEAC; ISSN: 0014-4886

L7 ANSWER 29 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Bankiewicz, Krys; Cunningham, Janet; Eberling, Jamie L.
TI Convection-enhanced delivery of AAV vectors to the CNS and therapeutic use thereof
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2

L7 ANSWER 30 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Schenk, Dale B.
TI Prevention and treatment of amyloidogenic disease, especially Alzheimer's
disease, based on induction of anti-amyloid immune response
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2

L7 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Breakefield, Xandra O.; Jacoby, David R.; Smith, Frances I.
TI HSV/AAV hybrid amplicon vector system for gene therapy of cancer,
deficiency state diseases and genetic disorders
SO U.S., 22 pp.
CODEN: USXXAM

L7 ANSWER 32 OF 54 MEDLINE DUPLICATE 8
AU Jacobs A; Breakefield X O; Fraefel C
TI HSV-1-based vectors for gene therapy of neurological diseases and brain
tumors: part II. Vector systems and applications.
SO NEOPLASIA, (1999 Nov) 1 (5) 402-16. Ref: 202
Journal code: 100886622. ISSN: 1522-8002.

L7 ANSWER 33 OF 54 MEDLINE DUPLICATE 9
AU Lo W D; Qu G; Sferra T J; Clark R; Chen R; Johnson P R
TI Adeno-associated virus-mediated gene transfer to the brain: duration and
modulation of expression.
SO HUMAN GENE THERAPY, (1999 Jan 20) 10 (2) 201-13.
Journal code: 9008950. ISSN: 1043-0342.

L7 ANSWER 34 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mi, Jie; Chatterjee, Saswati; Wong, Kamehameha K.; Forbes, Chelsea;
Lawless, George; Tobin, Allan J.

TI Recombinant adeno-associated virus (AAV) drives constitutive production of glutamate decarboxylase in neural cell lines
SO Journal of Neuroscience Research (1999), 57(1), 137-148
CODEN: JNREDK; ISSN: 0360-4012

L7 ANSWER 35 OF 54 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 10
AU Ozawa, K.; Fan, D.; Ogawa, M.; Urabe, M.; Kume, A.; Monahan, J.; Nakano, I.
TI Strategies for gene therapy of **Parkinson's disease** using **adeno-associated virus (AAV)** vectors
SO Biogenic Amines (1999), 15(1), 21-27
CODEN: BIAME7; ISSN: 0168-8561

L7 ANSWER 36 OF 54 SCISEARCH COPYRIGHT 2003 ISI (R)
AU Zhu J H (Reprint); Black P; Zhang L; Carter B; Kuo C J; Folkman J; Mulligan R C
TI Sustained inhibition of **brain tumor** growth by recombinant **adeno-associated virus** encoding endostatin
SO GENE THERAPY, (OCT 1999) Vol. 6, Supp. [1], pp. 1-1.
Publisher: STOCKTON PRESS, HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND.
ISSN: 0969-7128.

L7 ANSWER 37 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Breakefield, Xandra O.; Jacoby, David R.; Smith, Frances I.
TI Construction and therapeutic use of herpes simplex/adeno-associated virus hybrid amplicon vectors
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2

L7 ANSWER 38 OF 54 MEDLINE DUPLICATE 11
AU Mandel R J; Rendahl K G; Spratt S K; Snyder R O; Cohen L K; Leff S E
TI Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of **Parkinson's disease**.
SO JOURNAL OF NEUROSCIENCE, (1998 Jun 1) 18 (11) 4271-84.
Journal code: 8102140. ISSN: 0270-6474.

L7 ANSWER 39 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Fan, Dong-Sheng; Ogawa, Matsuo; Fujimoto, Ken-Ichi; Ikeguchi, Kunihiko; Ogasawara, Yoji; Urabe, Masashi; Kume, Akihiro; Nishizawa, Masatoyo; Nakano, Imaharu; Yoshida, Mitsuo; Ichinose, Hiroshi; Nagatsu, Toshiharu; Kurtzman, Gary J.; Ozawa, Keiya
TI Gene therapy of a rodent model of **Parkinson's disease** using **adeno-associated virus (AAV)** vectors
SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and Parkinson's Diseases), 647-652
CODEN: ADBBW; ISSN: 0099-6246

L7 ANSWER 40 OF 54 SCISEARCH COPYRIGHT 2003 ISI (R)
AU Leff S E (Reprint); Spratt S K; Snyder R O; Mandel R J
TI Long term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant **AAV** vector gene transfer in a rodent model of **Parkinson's disease**
SO EXPERIMENTAL NEUROLOGY, (OCT 1998) Vol. 153, No. 2, pp. 383-383.
Publisher: ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495.
ISSN: 0014-4886.

L7 ANSWER 41 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mizuno, Masaaki; Yoshida, Jun

TI Improvement of transduction efficiency of recombinant adeno-associated virus vector by entrapment in multilamellar liposomes
SO Japanese Journal of Cancer Research (1998), 89(4), 352-354
CODEN: JJCREP; ISSN: 0910-5050

L7 ANSWER 42 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mizuno, Masaaki; Yoshida, Jun; Colosi, Peter; Kurtzman, Gary
TI Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration
SO Japanese Journal of Cancer Research (1998), 89(1), 76-80
CODEN: JJCREP; ISSN: 0910-5050

L7 ANSWER 43 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mandel, R. J.; Spratt, S. K.; Snyder, R. O.; Leff, S. E.
TI Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
SO Proceedings of the National Academy of Sciences of the United States of America (1997), 94(25), 14083-14088
CODEN: PNASA6; ISSN: 0027-8424

L7 ANSWER 44 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU Leff, S. E.; Clevenger, D.; Wu, F.; Li, J.; John, J.; Snyder, R.; Kaspar, B.; Jaret, T.; Spratt, S. K.; Mandel, R. J.
TI Towards a gene therapy for Parkinson's disease (PD):
Intrastriatal injection of recombinant adeno-associated virus (rAAV) encoding human L-aromatic amino-acid decarboxylase (hAADC) in 6-OHDA lesioned rats restores AADC activity to control levels.
SO Society for Neuroscience Abstracts, (1997) Vol. 23, No. 1-2, pp. 541.
Meeting Info.: 27th Annual Meeting of the Society for Neuroscience, Part 1 New Orleans, Louisiana, USA October 25-30, 1997
ISSN: 0190-5295.

L7 ANSWER 45 OF 54 MEDLINE DUPLICATE 12
AU Johnston K M; Jacoby D; Pechan P A; Fraefel C; Borghesani P; Schuback D; Dunn R J; Smith F I; Breakefield X O
TI HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.
SO HUMAN GENE THERAPY, (1997 Feb 10) 8 (3) 359-70.
Journal code: 9008950. ISSN: 1043-0342.

L7 ANSWER 46 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU McQuiston, S. (1); Couto, L.; Fick, J.; Israel, M.; Kurtzman, G.; Podskoff, G.
TI Adeno-associated virus (AAV)
vector delivery of HSV-tk causes glioma regression after ganciclovir administration.
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1997) Vol. 38, No. 0, pp. 176.
Meeting Info.: Eighty-eighth Annual Meeting of the American Association for Cancer Research San Diego, California, USA April 12-16, 1997
ISSN: 0197-016X.

L7 ANSWER 47 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU Herrlinger, U. (1); Breakefield, X. O.; Jacoby, D.; Fraefel, C.; Spear, M. A.; Schuback, D.; Pechan, P. A.; Smith, F.; Johnston, K. M.
TI Transduction of human glioma cells by HSV/AAV hybrid vectors is increased by ionizing radiation.
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1997) Vol. 38, No. 0, pp. 13.
Meeting Info.: Eighty-eighth Annual Meeting of the American Association

for Cancer Research San Diego, California, USA April 12-16, 1997
ISSN: 0197-016X.

L7 ANSWER 48 OF 54 MEDLINE DUPLICATE 13
AU Okada H; Miyamura K; Itoh T; Hagiwara M; Wakabayashi T; Mizuno M; Colosi P; Kurtzman G; Yoshida J
TI Gene therapy against an experimental glioma using adeno-associated virus vectors.
SO GENE THERAPY, (1996 Nov) 3 (11) 957-64.
Journal code: 9421525. ISSN: 0969-7128.

L7 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Johnson, Philip R.
TI Recombinant adeno-associated virus vectors encoding immunodeficiency virus protein and their clinical use
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2

L7 ANSWER 50 OF 54 MEDLINE
AU Tenenbaum L; Darling J L; Hooghe-Peters E
TI Adeno-associated virus (AAV) as a vector for gene transfer into glial cells of the human central nervous system.
SO GENE THERAPY, (1994) 1 Suppl 1 S80.
Journal code: 9421525. ISSN: 0969-7128.

L7 ANSWER 51 OF 54 MEDLINE DUPLICATE 14
AU Wu P; Ziska D; Bonell M A; Grouzmann E; Millard W J; Meyer E M
TI Differential neuropeptide Y gene expression in post-mitotic versus dividing neuroblastoma cells driven by an adeno-associated virus vector.
SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1994 Jul) 24 (1-4) 27-33.
Journal code: 8908640. ISSN: 0169-328X.

L7 ANSWER 52 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU Bryant, S. O.; De Fiebre, C. M.; Notabartolo, D.; Wu, P.; King, M.; Meyer, E. M.
TI Use of reconstituted Sendai viral envelopes to deliver an NPY containing adeno-associated virus vector to neuroblastoma and brain cells.
SO Journal of the American Geriatrics Society, (1993) Vol. 41, No. 10 SUPPL., pp. SA2.
Meeting Info.: 50th Annual Scientific Meeting of the American Geriatrics Society and the 14th Annual Scientific Meeting of the American Federation for Aging Research New Orleans, Louisiana, USA November 15-19, 1993
ISSN: 0002-8614.

L7 ANSWER 53 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU De Fiebre, C. M.; Notabartolo, D.; Wu, P.; Meyer, F. M.
TI Use of reconstituted Sendai viral envelopes to deliver a NPY-containing adeno-associated virus vector to neuroblastoma and glial cells in culture.
SO Society for Neuroscience Abstracts, (1992) Vol. 18, No. 1-2, pp. 781.
Meeting Info.: 22nd Annual Meeting of the Society for Neuroscience Anaheim, California, USA October 25-30, 1992
ISSN: 0190-5295.

L7 ANSWER 54 OF 54 MEDLINE
AU Lipps B V; Mayor H D
TI Properties of adeno-associated virus (type 1) replicated in rodent cells by murine adenovirus.
SO JOURNAL OF GENERAL VIROLOGY, (1980 Nov) 51 (Pt 1) 223-7.
Journal code: 0077340. ISSN: 0022-1317.

=> d bib ab 31 37 49 17

L7 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1999:655915 CAPLUS
DN 131:282393
TI HSV/AAV hybrid amplicon vector system for gene therapy of cancer, deficiency state diseases and genetic disorders
IN Breakefield, Xandra O.; Jacoby, David R.; Smith, Frances I.
PA The General Hospital Corporation, USA
SO U.S., 22 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5965441	A	19991012	US 1997-968434	19971112
PRAI	US 1996-30694P	P	19961113		

AB The present invention relates to a hybrid vector system which incorporates elements of herpesvirus and adeno-assocd. virus and which is capable of expressing a gene product in eukaryotic cells. The vector system of the present invention provides a means of packaging plasmid DNA into highly infectious virions which can efficiently and safely deliver large transgenes to both mitotic and postmitotic cells in a state which can be maintained for extended periods. The invention pertains to the use of this vector system in introducing and expressing gene sequences in mitotic and postmitotic cells. This HSV/AAV hybrid amplicon vector system can be used in gene therapy for treating various cancers and deficiency state disorders.

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:344520 CAPLUS
DN 129:13209
TI Construction and therapeutic use of herpes simplex/adeno-associated virus hybrid amplicon vectors
IN Breakefield, Xandra O.; Jacoby, David R.; Smith, Frances I.
PA General Hospital Corp., USA; Eunice Kennedy Shriver Center for Mental Retardation, Inc.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9821345	A1	19980522	WO 1997-US20422	19971112
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9851999	A1	19980603	AU 1998-51999	19971112
	EP 946733	A1	19991006	EP 1997-946914	19971112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002503086	T2	20020129	JP 1998-522710	19971112
PRAI	US 1996-747919	A	19961112		
	WO 1997-US20422	W	19971112		

AB The present invention relates to a hybrid vector system which incorporates

elements of herpes simplex virus (HSV) and adeno-assocd. virus (AAV) which are capable of expressing a gene product in eukaryotic cells. The vector system of the present invention provides a means of packaging plasmid DNA into highly infectious virions which can efficiently and safely deliver large transgenes to both mitotic and postmitotic cells in a state which can be maintained for extended periods. The HSV amplicon elements comprise the DNA replication origin (oriS) and the virion packaging signal pac. The AAV elements are the DNA terminal repeats (ITRs) which are sufficient for replication and packaging of AAV virions, and the rep gene which encodes proteins for replication and chromosomal integration pf ITR-flanked sequences. The invention pertains to the use of this vector system in introducing and expressing gene sequences in mitotic and postmitotic cells for therapeutic purposes. Diseases and disorders potentially treatable include lysosomal storage disease, Lesch-Nyhan syndrome, amyloid polyneuropathy, Alzheimer's, Duchenne's muscular dystrophy, ALS, Parkinson's disease and brain tumors. Other treatable diseases are sickle-cell anemia, clotting disorders, thalassemias, cystic fibrosis, diabetes, liver and lung disorders, heart and vascular disease, hormone deficiency diseases, movement disorders, pain, and stroke. Treatable neoplastic-type diseases treatable include HIV tumors, neoplasms, carcinomas, sarcomas, leukemias, lymphoma, astrocytomas, oligodendroglomas, meningiomas, neurofibromas, ependymomas, Schwannomas, neurofibrosarcomas, and glioblastomas. The amplicon vector method is exemplified by administration of a cytochrome P 450 enzyme, cyclophosphamide, or ifosfamide as chemotherapeutic agent to CNS tumor cells.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1996:106583 CAPLUS
DN 124:137857
TI Recombinant adeno-associated virus vectors encoding immunodeficiency virus protein and their clinical use
IN Johnson, Philip R.
PA Children's Hospital, Inc., USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9534670	A2	19951221	WO 1995-US7178	19950606
	WO 9534670	A3	19960613		
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5658785	A	19970819	US 1994-254358	19940606
	CA 2192215	AA	19951221	CA 1995-2192215	19950606
	AU 9531243	A1	19960105	AU 1995-31243	19950606
	AU 710804	B2	19990930		
	EP 764213	A1	19970326	EP 1995-927113	19950606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10504185	T2	19980428	JP 1995-502305	19950606
	US 5786211	A	19980728	US 1995-475391	19950607
	US 5858775	A	19990112	US 1996-709609	19960910
	US 2002159979	A1	20021031	US 2002-77294	20020215
	US 2002187129	A1	20021212	US 2002-163886	20020604
PRAI	US 1994-254358	A	19940606		
	US 1995-466606	B1	19950606		
	WO 1995-US7178	W	19950606		
	US 1998-12132	B1	19980122		
	US 1999-292703	B1	19990415		
	US 2000-691604	A1	20001018		

AB The present invention provides adeno-assocd. virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, comprising adeno-assocd. virus inverted terminal repeats flanking DNA sequences encoding an immunodeficiency virus protein operably linked to promoter and polyadenylation sequences, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurol. disorders.

=>